$SAN (+1,33 %) achieved impressive sales growth of 8.6% to over 41 billion euros in 2024, largely supported by the strong sales of Dupixent and Beyfortus. Adjusted operating profit increased by 1.5% to 11.3 billion euros. However, adjusted net profit fell slightly to 8.9 billion euros due to higher research and development costs.
For 2025, Sanofi is planning a share buyback program worth 5 billion euros and forecasts an increase in adjusted earnings per share in the low double-digit percentage range. It is also targeting currency-adjusted sales growth in the mid to high single-digit percentage range.
Sanofi shares are currently trading at USD 52.15, with a daily high of USD 53.24 and a daily low of USD 52.00.
